Sign inCreate account

Report workspace tools

NCT02864784WITHDRAWNanonymous

A Prospective, Multicenter, Randomized, Placebo-Controlled, Two-armed, Double-blind Pilot Study to Evaluate the Safety, Tolerability and Efficacy of ACC vs. Placebo for the Treatment of Subjects With Castrate Resistant Prostate Cancer With Bone Metastasis

Sponsor

Source record

Amorphical Ltd.

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.

Indication / condition

AI-normalized

Castrate Resistant Prostate Cancer With Bone Metastasis

Intervention

Source record

Amorphous calcium carbonate, Placebo

Source & freshness

Source record

NCT ID

NCT02864784

Original source

ClinicalTrials.gov

Source last updated

Feb 28, 2024

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02864784

Title

A Prospective, Multicenter, Randomized, Placebo-Controlled, Two-armed, Double-blind Pilot Study to Evaluate the Safety, Tolerability and Efficacy of ACC vs. Placebo for the Treatment of Subjects With Castrate Resistant Prostate Cancer With Bone Metastasis

Sponsor

Amorphical Ltd.

Status

WITHDRAWN

Phase

Phase 1

Condition raw

Castrate Resistant Prostate Cancer With Bone Metastasis

Condition normalized

Castrate Resistant Prostate Cancer With Bone Metastasis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.

Target normalized

Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.

Interventions

Amorphous calcium carbonate, Placebo

Public preview

Source record

Amorphical Ltd.'s pilot study aims to evaluate the safety, tolerability, and efficacy of ACC in combination with standard treatments (Zoledronic Acid and Denosumab) for CRPC patients with bone metastasis. The market for CRPC therapies is significant, with increasing demand for effective adjunct treatments that can mitigate skeletal-related events (SREs) and improve patient quality of life. However, the study has been withdrawn due to budget constraints, which raises concerns about the financial viability and resource allocation of Amorphical Ltd. in advancing this asset. The competitive landscape includes established therapies like Zoledronic Acid and Denosumab, which may limit the adoption of new adjunct therapies unless compelling efficacy and safety data are presented.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Multicenter, Randomized, Placebo-Controlled, Two-armed, Double-blind Pilot Study to Evaluate the Safety, Tolerability and Efficacy of ACC vs. Placebo for the Treatment of Subjects With Castrate Resistant Prostate Cancer With Bone Metastasis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02864784

Status

WITHDRAWN

Phase

Phase 1

Sponsor

Amorphical Ltd.

Executive brief

Investment-Ready Snapshot

Amorphical Ltd.'s pilot study aims to evaluate the safety, tolerability, and efficacy of ACC in combination with standard treatments (Zoledronic Acid and Denosumab) for CRPC patients with bone metastasis. The market for CRPC therapies is significant, with increasing demand for effective adjunct treatments that can mitigate skeletal-related events (SREs) and improve patient quality of life. However, the study has been withdrawn due to budget constraints, which raises concerns about the financial viability and resource allocation of Amorphical Ltd. in advancing this asset. The competitive landscape includes established therapies like Zoledronic Acid and Denosumab, which may limit the adoption of new adjunct therapies unless compelling efficacy and safety data are presented.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 28, 2024
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02864784

Indication

Castrate Resistant Prostate Cancer With Bone Metastasis

Modality

small molecule

Target

Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.

Intervention

Amorphous calcium carbonate, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.